491 related articles for article (PubMed ID: 27839742)
1. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
2. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
3. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
11. Effects of rituximab in connective tissue disorders related interstitial lung disease.
Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
[TBL] [Abstract][Full Text] [Related]
12. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
[TBL] [Abstract][Full Text] [Related]
13. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
16. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
17. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
19. Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients.
Sari A; Guven D; Armagan B; Erden A; Kalyoncu U; Karadag O; Apras Bilgen S; Ertenli I; Kiraz S; Akdogan A
J Clin Rheumatol; 2017 Dec; 23(8):411-415. PubMed ID: 28926468
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
